ABclonal www.abclonal.com

Human LAG-3 Monoclonal Antibody

Catalog No.: YR0133

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility

0.2 µm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an antitumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer.Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Reported Applications

ELISA,neutralization,function al assays such as bioanalytical PK and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone

Relatlimab Biosimilar

human IgG4 kappa

Isotype

Immunogen

Human LAG-3

RecommendedIsotype Control(s)

In Vivo Grade Recombinant Human IgG4-S228P Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 6.0

Contact

 \odot

www.abclonal.com

Product Information

Production

Purification

Purified from cell culture supernatant in an Protein A or G purification animal-free facility

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)